Skip to main content
. 2017 Feb 10;7:42412. doi: 10.1038/srep42412

Figure 3. BrPA reduces inflammation by increasing Treg cells and decreasing DCs.

Figure 3

Either BrPA (5 mg/kg) or NS was subcutaneously administered to ZyA-treated arthritic SKG mice. Each group was 5 mice. (A) Clinical arthritis scores were determined up to 48 days after ZyA injection. (B, D) Splenocytes from BrPA- or NS-treated arthritic SKG mice were stained with anti-CD4, anti-interferon (IFN)-γ, anti-interleukin (IL)-17, anti-Foxp3, and anti-CD25 antibodies, and analyzed by flow cytometry. (C, E) Frequency of IFNγ + , IL-17 + , Foxp3 + CD25 + , and Foxp3 + cells among the CD4 + cells in the spleen of BrPA- or NS-treated SKG mice, analyzed by flow cytometry. (F, G) Splenocytes from BrPA- or NS-treated SKG mice were stained with antibodies against CD11b, CD11c, CD80, CD86, and CD40 and analyzed by flow cytometry (left). Frequency of CD86 + CD40 + and CD86 + CD80 + DCs among the CD11b + CD11c + cells, analyzed by flow cytometry (right). Bars show mean ± SEM. *P < 0.05; **P < 0.01. n.s. = not significant (see Fig. 2 for other definitions).